Immunocore Holdings PLC Sponsored ADR
IMCR Healthcare Biotechnology
Immunocore Holdings PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $400.0 million, up 29.0% from fiscal 2024. In the quarter to June 2026, revenue grew 18.3%, EPS grew 92.1%, free cash flow fell 40.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow IMCR
Immunocore Holdings PLC Sponsored ADR (IMCR) EV/Sales
As of 16 October 2026, Immunocore Holdings PLC Sponsored ADR (IMCR) trades at a EV/Sales of 2.5×. Over the past ten years it has ranged from 0.0× (June 2021) to 39.7× (November 2021); the current reading is higher than 8% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.3× | (6.06%) |
| FY2024 | 3.5× | (71.72%) |
| FY2023 | 12.5× | (0.34%) |
| FY2022 | 12.5× | (62.48%) |
| FY2021 | 33.3× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.7× | 0.37% |
| Mar 2026 | 2.7× | (17.54%) |
| Dec 2025 | 3.3× | (8.88%) |
| Sep 2025 | 3.6× | 13.98% |
| 20 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MAZE Maze Therapeutics, Inc. compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. compare | 1.7× |
| IMCR Immunocore Holdings PLC Sponsored ADR | 2.5× |
| ANAB AnaptysBio, Inc. compare | 4.5× |
| KRSA Korsana Biosciences, Inc. compare | 8.8× |
| NTLA Intellia Therapeutics, Inc. compare | 18.3× |
| QURE uniQure N.V. compare | 36.8× |
| ABSI Absci Corporation compare | 704× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)